|
GWAS dataset
|
Method
|
OR/betaa
|
95% CI
|
P value
|
|---|
|
IGAP AD
|
IVW
|
0.93
|
0.80−1.09
|
3.85E−01
|
|
Weighted median
|
1.01
|
0.83−1.23
|
9.25E−01
|
|
MR-Egger
|
1.09
|
0.85−1.40
|
4.90E−01
|
|
MR-PRESSO
|
0.93
|
0.81−1.08
|
3.80E−01
|
|
UK Biobank AD proxy
|
IVW
|
0.93
|
0.88−0.98
|
7.00E−03
|
|
Weighted median
|
0.92
|
0.87−0.97
|
2.00E−03
|
|
MR-Egger
|
0.91
|
0.85−0.98
|
9.00E−03
|
|
MR-PRESSO
|
0.93
|
0.88−0.98
|
2.30E−02
|
|
Maternal AD group from UK Biobank
|
IVW
|
0.89
|
0.84−0.94
|
7.29E−05
|
|
Weighted median
|
0.87
|
0.82−0.93
|
3.30E−05
|
|
MR-Egger
|
0.87
|
0.80−0.94
|
1.00E−03
|
|
MR-PRESSO
|
0.89
|
0.85−0.93
|
6.65E−04
|
|
Paternal AD group from UK Biobank
|
IVW
|
1.02
|
0.92−1.12
|
7.59E−01
|
|
Weighted median
|
1.00
|
0.92−1.10
|
9.25E−01
|
|
MR-Egger
|
0.99
|
0.86−1.14
|
9.08E−01
|
|
MR-PRESSO
|
1.02
|
0.92−1.12
|
7.66E−01
|
|
Cognitive performance
|
IVW
|
0.007
|
[−0.043, 0.057]
|
0.775
|
|
Weighted median
|
−0.012
|
[−0.050, 0.026]
|
0.546
|
|
MR-Egger
|
−0.019
|
[−0.100, 0.061]
|
0.638
|
|
MR-PRESSO
|
0.007
|
[−0.043, 0.057]
|
0.781
|
- OR odds ratio, CI confidence interval, IVW inverse-variance weighted, IGAP International Genomics of Alzheimer’s Project, MR-PRESSO Mendelian randomization pleiotropy residual sum and outlier; the significance of suggestive association between vitamin C levels and AD was at P < 0.05; the significance of statistically significant association between vitamin C levels and AD was at Bonferroni-corrected significance P < 0.05/4 = 0.0125. aOR for AD and AD proxy phenotype, and beta for cognitive performance
